Literature DB >> 15946909

Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?

David Czock1, F M Rasche.   

Abstract

BACKGROUND: Dose adjustments of antimicrobial drugs are necessary in renal failure. One method of dose adjustment is to reduce the dose and the other is to prolong the administration interval in proportion to the reduced drug clearance. Pharmacokinetically, both methods involve an identical drug exposure but pharmacodynamically there may be differences. It is not known which dose adjustment method is preferable in patients with renal failure.
METHODS: We performed simulations using a published mechanism-based pharmacokinetic/ pharmacodynamic model of ciprofloxacin effects on growth and death of Escherichia coli bacteria. Ciprofloxacin 500 mg every 12 hrs was selected as the standard dose. In renal failure either the dose was reduced (250 mg every 12 hrs) or the administration interval was prolonged (500 mg every 24 hrs) in proportion to the reduced ciprofloxacin clearance. Simulations were done with use of a commercial software package.
RESULTS: In normal renal function, using the standard dose, bacterial eradication was predicted on day 3. In renal failure, bacterial eradication was predicted on day 3 when using the interval prolongation scheme but only on day 6 when using the dose reduction scheme. The relationship between the efficacies of these 3 dosage schemes could have been predicted by AUC above MIC and AUIC, but not by AUC/MIC or time above MIC.
CONCLUSION: Prolongation of the administration interval may be the preferable dose adjustment method in renal failure with ciprofloxacin. We hypothesize that these results may be transferable to other so-called dose-dependent antimicrobial drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15946909

Source DB:  PubMed          Journal:  Eur J Med Res        ISSN: 0949-2321            Impact factor:   2.175


  7 in total

Review 1.  Drug therapy in patients with chronic renal failure.

Authors:  Bertram Hartmann; David Czock; Frieder Keller
Journal:  Dtsch Arztebl Int       Date:  2010-09-17       Impact factor: 5.594

2.  General principles of antimicrobial therapy.

Authors:  Surbhi Leekha; Christine L Terrell; Randall S Edson
Journal:  Mayo Clin Proc       Date:  2011-02       Impact factor: 7.616

Review 3.  Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunction.

Authors:  Frieder Keller; Bernd Schröppel; Ulla Ludwig
Journal:  World J Nephrol       Date:  2015-07-06

4.  Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency.

Authors:  Samir K Gupta; Suzanne K Swan; Thomas Marbury; William Smith; Sherwyn Schwartz; Karen Kolz; David L Cutler
Journal:  Br J Clin Pharmacol       Date:  2007-06-06       Impact factor: 4.335

Review 5.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of antimicrobial drug effects.

Authors:  David Czock; Frieder Keller
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-09-29       Impact factor: 2.410

6.  Analysis of fluoroquinolones in dusts from intensive livestock farming and the co-occurrence of fluoroquinolone-resistant Escherichia coli.

Authors:  Jochen Schulz; Nicole Kemper; Joerg Hartung; Franziska Janusch; Siegrun A I Mohring; Gerd Hamscher
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

7.  Medicine Dose Adjustment Practice and Associated Factors among Renally Impaired Patients in Amhara Regional State, Ethiopia.

Authors:  Tirsit Kestela Zeleke; Tilahun Yemanu Birhan; Ousman Abubeker Abdela
Journal:  Int J Nephrol       Date:  2021-12-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.